Can-Fite BioPharma Management

Management criteria checks 4/4

Can-Fite BioPharma's CEO is Motti Farbstein, appointed in Aug 2003, has a tenure of 20.75 years. total yearly compensation is $467.00K, comprised of 66.4% salary and 33.6% bonuses, including company stock and options. directly owns 0% of the company’s shares, worth $8.39. The average tenure of the management team and the board of directors is 20.8 years and 15.8 years respectively.

Key information

Motti Farbstein

Chief executive officer

US$467.0k

Total compensation

CEO salary percentage	66.4%
CEO tenure	20.8yrs
CEO ownership	0.00008%
Management average tenure	20.8yrs
Board average tenure	15.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Motti Farbstein's remuneration changed compared to Can-Fite BioPharma's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$467k	US$310k	-US$8m
Sep 30 2023	n/a	n/a	-US$9m
Jun 30 2023	n/a	n/a	-US$10m
Mar 31 2023	n/a	n/a	-US$10m
Dec 31 2022	US$471k	US$298k	-US$10m
Sep 30 2022	n/a	n/a	-US$14m
Jun 30 2022	n/a	n/a	-US$15m
Mar 31 2022	n/a	n/a	-US$16m
Dec 31 2021	US$484k	US$291k	-US$15m
Sep 30 2021	n/a	n/a	-US$12m
Jun 30 2021	n/a	n/a	-US$11m
Mar 31 2021	n/a	n/a	-US$12m
Dec 31 2020	US$468k	US$313k	-US$15m
Sep 30 2020	n/a	n/a	-US$13m
Jun 30 2020	n/a	n/a	-US$17m
Mar 31 2020	n/a	n/a	-US$13m
Dec 31 2019	US$277k	US$195k	-US$13m
Sep 30 2019	n/a	n/a	-US$11m
Jun 30 2019	n/a	n/a	-US$8m
Mar 31 2019	n/a	n/a	-US$7m
Dec 31 2018	US$331k	US$186k	-US$7m
Sep 30 2018	n/a	n/a	-US$5m
Jun 30 2018	n/a	n/a	-US$6m
Mar 31 2018	n/a	n/a	-US$5m
Dec 31 2017	US$315k	US$242k	-US$6m

Compensation vs Market: Motti's total compensation ($USD467.00K) is below average for companies of similar size in the US market ($USD674.46K).

Compensation vs Earnings: Motti's compensation has been consistent with company performance over the past year.

CEO

Motti Farbstein (59 yo)

20.8yrs

Tenure

US$467,000

Compensation

Mr. Motti Farbstein serves as a Chief Operating and Financial Officer at Can-Fite BioPharma Ltd. since May 2005 and serves as its Chief Executive Officer since June 30, 2023. Mr. Farbstein served as Chief...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Pnina Fishman	Founder	18.7yrs	US$703.00k	0.018% $ 1.8k
Motti Farbstein	CEO and Chief Financial & Operating Officer	20.8yrs	US$467.00k	0.000080% $ 8.4
Sari Fishman	Vice President of Business Development	10.3yrs	US$373.00k	no data
Ilan Cohn	Co-Founder & Director	29.7yrs	no data	0.0089% $ 935.3
Stephen A. Harrison	Member of Clinical Advisory Board & Consulting Chief Medical Officer	less than a year	no data	no data

20.8yrs

Average Tenure

64yo

Average Age

Experienced Management: CANF's management team is seasoned and experienced (20.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Pnina Fishman	Founder	18.7yrs	US$703.00k	0.018% $ 1.8k
Ilan Cohn	Co-Founder & Director	30.3yrs	no data	0.0089% $ 935.3
Stephen A. Harrison	Member of Clinical Advisory Board & Consulting Chief Medical Officer	no data	no data	no data
Nabil Hanna	Member of Scientific Advisory Board	no data	no data	no data
Yaacov Goldman	External Independent Director	6.8yrs	US$60.00k	no data
Abraham Sartani	Independent Director	23.3yrs	no data	no data
Guy Regev	Independent External Director	12.8yrs	US$60.00k	0.0016% $ 169.9
Scott L. Friedman	Member of Clinical Advisory Board	no data	no data	no data
Arun Sanyal	Member of Clinical Advisory Board	no data	no data	no data
Yoseph Bornstein	Independent External Director	2.8yrs	no data	no data
Rifaat Safadi	Member of Clinical Advisory Board	no data	no data	no data
Kim Papp	Member of Clinical Advisory Board	no data	no data	no data

15.8yrs

Average Tenure

69yo

Average Age

Experienced Board: CANF's board of directors are seasoned and experienced ( 15.8 years average tenure).

Can-Fite BioPharma Management

Management criteria checks 4/4

Key information

Recent management updates

Can-Fite BioPharma Ltd., Annual General Meeting, Jul 31, 2023

Can-Fite BioPharma Ltd., Annual General Meeting, Aug 29, 2022

Can-Fite BioPharma Ltd., Annual General Meeting, Dec 09, 2020

Recent updates

Can-Fite BioPharma Ltd. Reports New Data on Namodenoson’s Anti-Obesity Mechanism of Action

Can-Fite BioPharma Ltd. Receives Positive Response from U.S. Food and Drug Administration on Pediatric Study Plan for Treatment of Children Suffering from Psoriasis with Piclidenoson

Can-Fite BioPharma Ltd. Completes the Design of a Phase IIa Study Protocol for the Treatment of Pancreatic Cancer Patients

Can-Fite Biopharma Ltd. Announces Complete Response and 6.9 Years Overall Survival in A Patient with Advanced Liver Cancer Treated with Namodenoson

Can-Fite Biopharma Ltd. Provides Business Update

Can-Fite Biopharma Ltd. Announces Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal

Can-Fite Enters Rare Genetic Disease Field Based on Impactful Findings of A Fondazione Telethon and Naples University Researcher Showing Piclidenoson Is Efficacious in Treating Lowe Syndrome

Can-Fite Biopharma Ltd. Submits Pediatric Plan to U.S. Food and Drug Administration to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis

Can-Fite Biopharma Ltd. Receives U.S. FDA's Go Ahead for Piclidenoson Psoriasis Registration Plan

Can-Fite BioPharma Ltd., Annual General Meeting, Jul 31, 2023

Can-Fite BioPharma Ltd. to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson

Can-Fite BioPharma Ltd. to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients

Can-Fite Biopharma Ltd. Announces Namodenoson Is Approved for Compassionate Use in the Treatment of Liver Cancer in Israel and Romania

Can-Fite BioPharma Ltd. Announces Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies

Can-Fite BioPharma Ltd. Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; U.S. Food and Drug Administration Submission to Follow

Can-Fite Biopharma Ltd Provides Update on Its Clinical Program for Namodenoson in the Treatment of Hepatocellular Carcinoma

Can-Fite BioPharma Ltd.: New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy Presented by KOL Dr. Papp at the 31st European Academy of Dermatology

Can-Fite BioPharma Ltd’s Drug Namodenoson Approves for Compassionate Use Treatment of Advanced Liver Cancer Patients in Romania

Can-Fite BioPharma Ltd. Reports Progress in the Development of Piclidenoson for Osteoarthritis in Pets Through Its Partner Vetbiolix

Can-Fite BioPharma Ltd., Annual General Meeting, Aug 29, 2022

Can-Fite BioPharma Ltd. to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis

Can-Fite BioPharma Ltd. Announces Positive Top-Line Results from Piclidenoson Phase III COMFORT Study in Moderate to Severe Psoriasis

Can-Fite BioPharma Ltd. Receives Key NASH Patent in Israel

Can-Fite Biopharma Ltd. Announces It Is Developing A Topical Psoriasis Treatment with Piclidenoson, Its Phase III Psoriasis Oral Drug Candidate

Can-Fite BioPharma Ltd. Announces Top Line Data from its Phase III Comfort™ Study of Piclidenoson in Treatment of Moderate-To-Severe Plaque Psoriasis to Be Release in the Second Quarter of 2022

Can Fite Announces First Patient Enrolled in Phase IIb NASH Clinical Trial with Namodenoson

Can-Fite BioPharma Ltd. Announces Pre-Clinical Studies with Skin Cells, Modeling Psoriasis in Humans

Can-Fite Biopharma Ltd Files Patent Applications for the Treatment of Various Advanced Solid Tumors

Liver Cancer Patient Treated with Can-Fite’s Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study

Can-Fite Biopharma Ltd. Announces Phase III Psoriasis Study to Complete 16-Week Treatment of Last Patient in January

Can-Fite Biopharma Ltd. Commences Clinical Study for the Treatment of Canine Osteoarthritis

Can-Fite BioPharma Ltd. Completes Patient Enrollment in Phase III Psoriasis Study

Can-Fite BioPharma Ltd Receives Notice of Patent Allowance in China for NASH Treatment

Can-Fite Biopharma Ltd. to Initiate Phase IIb Nash Study with its Drug Candidate Namodenoson

Can-Fite BioPharma Ltd. Provides Clinical Update

Can-Fite Biopharma Ltd. Announces That 75% of Patients Enrolled in Its Phase III Comfort Study

Can-Fite BioPharma Ltd. Announces New Data from Preclinical Study of Its Drug Candidate CF602 in the Treatment of Erectile Dysfunction in Diabetes Experimental Model

Can-Fite Enrolls First Patient in Phase II COVID-19 Study Under FDA Protocol

Can-Fite Biopharma Ltd. Announces New Data from the Phase Ii Advanced Liver Cancer Study

Can-Fite Announces Inhibition of Liver Fibrosis by Cannabis Compounds in Preclinical Studies

Can-Fite BioPharma Ltd Announces Publication of Namodenoson Liver Cancer Study in Peer Reviewed Journal—Cancers

Can-Fite Biopharma Ltd. Receives Israel Ministry of Health Approval to Conduct Research with Cannabinoids in Cancer, Inflammation and Obesity at the Company Discovery Labs

Can-Fite BioPharma Ltd. Announces Namodenoson Drug Candidate for Non-Alcoholic Steatohepatitis Treatment

Can-Fite BioPharma Ltd., Annual General Meeting, Dec 09, 2020

Can-Fite BioPharma Ltd. to Report Q3, 2020 Results on Nov 30, 2020

Can-Fite Biopharma Ltd. Announces That Dr. Rifaat Safadi, Principal Investigator of the Company's Phase Ii Study of Namodenoson in the Treatment of Nafld/Nash Delivered A Late-Brweaking Oral Presentation At the Aasld Conference

Can-Fite BioPharma Ltd. Announces Positive Phase III Psoriasis Interim Data Analysis

Can-Fite BioPharma Ltd. to Report Q2, 2020 Results on Aug 27, 2020

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age